A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer
7. Mai 2019 aktualisiert von: Case Comprehensive Cancer Center
A Pilot Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer
Participants are asked to participate in a research study of the effect of a sleep intervention on improving sleep habits and reducing their risk of breast cancer.
Participants are asked to participate in this research study because they have been identified as being at higher than average risk of developing breast cancer.
The purpose of this study is to compare women who get a sleep intervention to women who do not get a sleep intervention. This study team will compare these two groups of women to see if the sleep intervention improves their sleep and if it lowers markers of inflammation that have been associated with an increased risk of breast cancer.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Detaillierte Beschreibung
Objective 1: To test the effectiveness of the GO! To Sleep program at improving the sleep duration and sleep quality in women at high risk of breast cancer.
Objective 2: To test the effectiveness of improvements in sleep quality and/or duration due to the GO! To Sleep program on biomarkers of inflammation in women at high risk of breast cancer.
Objective 3: To evaluate the effectiveness of improvements in health-related quality of life after the GO! To Sleep in women at high risk of breast cancer.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
17
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
21 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Weiblich
Beschreibung
Inclusion Criteria:
Women at high risk of breast cancer due to one or more of the following:
- Carry deleterious mutations in the BRCA1, BRCA2, PTEN, TP53, STK11, or CDH1 genes
- Previous diagnosis of lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)
- Lifetime risk of 20% or greater as calculated by the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool or the Tyrer-Cuzick IBIS Risk Assessment Tool
- Ability to access the internet and watch videos online.
- Valid email address.
- Self-reported sleep duration of 6 hours per night or less
Exclusion Criteria:
- Previous diagnosis of cancer.
- Lack of ability to read and converse in English.
- Lack of ability to give informed consent.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: GO! To Sleep
Participants in the intervention group will be provided with a code and website address to participate in this program.
This program includes reminder emails and is 6 weeks in duration.
Participants will be given a blood draw to measure biomarkers.
|
Controlled sleep intervention.
Provide online education and reminder emails on improving sleep behavior
blood sample measured for stress and sleep markers
Andere Namen:
Assessment of sleep quality.
This is a continuous measure from 0 (best) to 21 (worst).
Sleep duration will be obtained directly from responses.
|
|
Aktiver Komparator: informational control
Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
|
blood sample measured for stress and sleep markers
Andere Namen:
Assessment of sleep quality.
This is a continuous measure from 0 (best) to 21 (worst).
Sleep duration will be obtained directly from responses.
Participants will receive weekly emails on the health benefits of sleep for 6 weeks
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groups
Zeitfenster: Change from baseline to post intervention, around 8 weeks after baseline
|
Sleep quality will be measured by the PSQI which is a continuous measure from 0 (best) to 21 (worst)
|
Change from baseline to post intervention, around 8 weeks after baseline
|
|
Difference in change in Insomnia Severity Index (ISI) score between groups
Zeitfenster: Change from baseline to post intervention, around 8 weeks after baseline
|
Sleep quality will be measured with the insomnia severity index (ISI).
A validated instrument for sleep quality
|
Change from baseline to post intervention, around 8 weeks after baseline
|
|
Difference in change in sleep duration between groups
Zeitfenster: Change from baseline to post intervention, around 8 weeks after baseline
|
Sleep duration will be obtained by self-report from responses to the PSQI
|
Change from baseline to post intervention, around 8 weeks after baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in change of SF-12 score from baseline to post-intervention between groups
Zeitfenster: Change from baseline to 6 months post intervention
|
The effectiveness of changing health-related quality of life after the GO!
To Sleep program will he measured with the self-reported survey SF-12
|
Change from baseline to 6 months post intervention
|
|
Correlation of joint changes in biomarker levels with PSQI and ISI
Zeitfenster: Change from baseline to 6 months post intervention
|
This study will correlate the joint changes in biomarker level with the changes in sleep quality and sleep duration
|
Change from baseline to 6 months post intervention
|
|
Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groups
Zeitfenster: Change from baseline to 6 months post intervention
|
Long term sleep quality will be measured by the PSQI which is a continuous measure from 0 (best) to 21 (worst)
|
Change from baseline to 6 months post intervention
|
|
Difference in change in Insomnia Severity Index (ISI) score between groups
Zeitfenster: Change from baseline to 6 months post intervention
|
Sleep quality will be measured with the insomnia severity index (ISI).
A validated instrument for sleep quality
|
Change from baseline to 6 months post intervention
|
|
Difference in change in sleep duration between groups
Zeitfenster: Change from baseline to 6 months post intervention
|
Sleep duration will be obtained by self-report from responses to the PSQI
|
Change from baseline to 6 months post intervention
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Cheryl Thompson, PhD, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
4. August 2015
Primärer Abschluss (Tatsächlich)
23. März 2017
Studienabschluss (Tatsächlich)
23. Juli 2017
Studienanmeldedaten
Zuerst eingereicht
23. November 2015
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
23. November 2015
Zuerst gepostet (Schätzen)
25. November 2015
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
9. Mai 2019
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
7. Mai 2019
Zuletzt verifiziert
1. Mai 2019
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CASE6114
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .